ArticleTranslational lung cancer research2025
Feasibility of next-generation sequencing using bronchoscopic specimens in potentially resectable non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With advances in multimodal treatment, the importance of identifying biomarkers by bronchoscopy has increased, even in potentially resectable non-small cell lung cancer (NSCLC). However, it remains unclear whether next-generation sequencing (NGS) using bronchoscopic specimens is as useful in potentially resectable NSCLC as in unresectable cases. The objective of this study was to evaluate the feasibility of performing NGS using bronchoscopic specimens obtained from patients with potentially resectable NSCLC. Methods: The patients diagnosed with NSCLC via bronchoscopy at National Cancer Center Hospital who underwent NGS were retrospectively analyzed. We allocated all N0-2 and M0 and N3 and/or M1 cases to the potentially resectable and unresectable groups, respectively. Patients were divided into three subgroups according to the target: endobronchial, peri-tracheal/bronchial, and lung lesions. The NGS analytical success rates for potentially resectable NSCLC were compared with unresectable cases for each subgroup to investigate the feasibility of NGS-targeted bronchoscopy. Results: Among the 644 patients, 184 had potentially resectable disease, and 460 had unresectable disease. The overall NGS analytical success rate was significantly lower in the potentially resectable group than in unresectable group (81.0% Conclusions: The overall rate of successful NGS analysis using bronchoscopic specimens were lower in potentially resectable NSCLC cases, especially in lung lesions. To improve NGS feasibility, it is important to adequately harvest lung lesions and prioritize targeting endobronchial or peri-tracheal/bronchial lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.